FTRE
FortreaANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Post-earnings evidence improved: Q1 adjusted EPS of $0.16 beat third-party consensus of $0.03 and revenue of $636.5 million beat third-party consensus near $628.5 million, while guidance was reaffirmed. Delayed Street reaction skewed constructive on May 6, with Citigroup raising its target to $20 from $16 and Barclays raising to $16 from $11 while keeping Hold.
Posture
Constructive
Lead driver
Momentum
What changed
2 setup hits (3d) with net bullish as of 2026-06-03.
What can break
Backlog is not a clean revenue proxy: the 10-Q says many contracts have 30-90 day termination provisions and backlog can be affected by delays, scope changes, and cancellations [#10-Q-2026-05-05].
Momentum
96
Value
49
Sentiment
44
Setup hits (3d)
2 · Net Bullish
AI TargetsBase $14.80 · Bull $20.00 · Bear $10.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-08 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Bullish
Target $14.80
Why
Momentum96 · Δ7d +1.2
Value49 · Δ7d +0.1
Sentiment44 · Δ7d -15.4
So what
Strength-led posture (Net Bullish). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
96
34% active weight
Current posture
7d trendFlat
Δ7d
+1.2
Δ21d
+6.1
Value
49
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.4
Sentiment
44
33% active weight
Current posture
7d trendSoftening
Δ7d
-15.4
Δ21d
+2.7
Why this grade
Composite grade A. Momentum 95.6 / Value 48.6 / Sentiment 44.1
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$1.45B
Beta
-
Shares Out
92.4M
P/E (TTM) · Derived
-1.5
P/S (TTM)
0.56
P/FCF (TTM)
6.47
Rev YoY
+3.9%
EPS YoY
+17.7%
Gross Margin
+18.6%
Op Margin
-33.1%
Net Debt
$1.01B
Current Ratio
1.00
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology